https://www.taxtmi.com/news?id=2325 Policy continues to permit full foreign direct investment for newly established pharmaceutical ventures to promote manufacturing capacity, technology acquisition, and sector development, while inbound investment into existing firms is allowed only for a limited transitional period subject to prior approval by the designated investment approval authority; competition oversight will be strengthened to review mergers and acquisitions and balance public health concerns with investment attraction. en-us Wed, 12 Oct 2011 16:14:30 +0530 Wed, 12 Oct 2011 16:14:30 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=2325 Policy continues to permit full foreign direct investment for newly established pharmaceutical ventures to promote manufacturing capacity, technology acquisition, and sector development, while inbound investment into existing firms is allowed only for a limited transitional period subject to prior approval by the designated investment approval authority; competition oversight will be strengthened to review mergers and acquisitions and balance public health concerns with investment attraction. News - Wed, 12 Oct 2011 16:14:30 +0530 https://www.taxtmi.com/news?id=2325